Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 74

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Colitis ulcerative

Not recruiting

Study on the Use of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treating Ulcerative Colitis in Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Midtjylland

Oesophageal adenocarcinoma

Not recruiting

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Colorectal cancer+1

Not recruiting

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Catharina Ziekenhuis Stichting

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:pharmaand GmbH

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Colorectal cancer

Not recruiting

Study of organ preservation using chemoradiotherapy and transanal surgery compared to standard surgery in patients with early rectal cancer (STAR-TREC trial)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:The University Of Birmingham

Colorectal adenocarcinoma

Not recruiting

Study on the Effectiveness of FOLFOX and Panitumumab for Patients with Metastatic Colorectal Cancer Without RAS Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Colitis ulcerative

Not recruiting

Study on the Effects of Hyperbaric Oxygen Therapy for Patients with Moderate-to-Severe Ulcerative Colitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Amsterdam UMC Stichting

Malignant peritoneal neoplasm+2

Not recruiting

Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Oscar Lambret

Malignant peritoneal neoplasm+2

Not recruiting

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rectal cancer stage III

Not recruiting

Study on Short-Course Radiotherapy and Chemotherapy with Fluorouracil, Irinotecan, and Oxaliplatin for Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Alveolar bone defect

Not recruiting

Study on Alveolar Bone Augmentation Using Mesenchymal Stem Cells and Biphasic Calcium Phosphate for Patients with Jaw Bone Defects

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mesenchymal Stromal Cells, Ex Vivo Cultured
  • Sponsor:University of Bergen

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.